1
|
Vue NC, Sassani J, Prairie B, Yin Y, Krivak TC, Crafton S, Morse C, Nakayama J, Wield A, Horne ZD, Miller EM. Clinical outcomes with utilization of high-potency topical steroids in patients with lichen sclerosus-associated vulvar cancer. Gynecol Oncol 2024; 187:58-63. [PMID: 38733953 DOI: 10.1016/j.ygyno.2024.05.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/02/2024] [Revised: 04/06/2024] [Accepted: 05/05/2024] [Indexed: 05/13/2024]
Abstract
OBJECTIVES To evaluate the impact of high-potency topical steroid use on risk of recurrence of lichen sclerosus-associated vulvar cancer. METHODS This is a retrospective cohort study evaluating patients with lichen sclerosus (LS)- associated vulvar squamous cell cancer (VSCC). Demographic and clinical outcome data were compared between two comparison groups: patients who received steroids, mainly clobetasol, and patients who did not receive steroids following treatment of LS-related vulvar cancer. Categorical variables were compared using Fisher's exact test or chi-square test. Continuous variables were compared using a two-sided student's t-test. Time to recurrence (TTR) and overall survival (OS) were analyzed using Kaplan-Meier survival plot and compared using Mantel-Cox log rank test. Cox proportional hazard regression models were conducted to generate hazard ratios for both TTR and OS. A p value of <0.05 was considered statistically significant. RESULTS A total of 49 patients were included, with 36 patients receiving steroid treatment and 13 patients in the expectant management group. The median age of diagnosis was 68. The average BMI was 31.7 +/- 7.0. The median length of follow up was 41 months. The majority of patients were diagnosed with stage I VSCC. There was no difference in demographics or oncologic management of vulvar cancer between the two cohorts. Overall recurrence was decreased among patients who received steroid treatment when compared to patients who did not, 12 patients (33.3%) versus 9 patients (69.2%) respectively (p = 0.048). CONCLUSIONS High-potency topical steroid use following treatment of lichen sclerosus-associated vulvar squamous cell carcinoma is associated with decreased risk of recurrence and prolonged median time to recurrence.
Collapse
Affiliation(s)
- Nujsaubnusi C Vue
- Division of Gynecologic Oncology, Allegheny Health Network Cancer Institute, Pittsburgh, PA, USA.
| | - Jessica Sassani
- Division of Urogynecology, Allegheny Health Network, Pittsburgh, PA, USA
| | - Beth Prairie
- Division of Gynecologic Oncology, Allegheny Health Network Cancer Institute, Pittsburgh, PA, USA
| | - Yue Yin
- Allegheny Singer Research Institute, Allegheny Health Network, Pittsburgh, PA, USA
| | - Thomas C Krivak
- Division of Gynecologic Oncology, Allegheny Health Network Cancer Institute, Pittsburgh, PA, USA
| | - Sarah Crafton
- Division of Gynecologic Oncology, Allegheny Health Network Cancer Institute, Pittsburgh, PA, USA
| | - Christopher Morse
- Division of Gynecologic Oncology, Allegheny Health Network Cancer Institute, Pittsburgh, PA, USA
| | - John Nakayama
- Division of Gynecologic Oncology, Allegheny Health Network Cancer Institute, Pittsburgh, PA, USA
| | - Alyssa Wield
- Division of Gynecologic Oncology, Allegheny Health Network Cancer Institute, Pittsburgh, PA, USA
| | - Zachary D Horne
- Division of Radiation Oncology, Allegheny Health Network Cancer Institute, Pittsburgh, PA, USA
| | - Eirwen M Miller
- Division of Gynecologic Oncology, Allegheny Health Network Cancer Institute, Pittsburgh, PA, USA
| |
Collapse
|
2
|
McGreal K, Crafton S, David J, Stets CW, Grosenbacher N, Chen JL, Hays JL. Identifying targetable markers of resistance to dual TORC1/2 inhibition in endometrial cancer cell lines. J Clin Oncol 2022. [DOI: 10.1200/jco.2022.40.16_suppl.e17633] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e17633 Background: For patients with endometrial cancer, the PI3K/AKT/mTOR pathway is an attractive target due to dysregulation of the pathway secondary to commonly found genetic alterations. Previous trials of mTOR inhibitors in endometrial cancer have shown modest clinical activity and tolerability. Here we present a proteomics based approach to identify novel partners that will enhance the efficacy of dual TORC1/2 inhibition. Methods: Five endometrial cell lines (AN3CA, ECC, HEC1A, HEC1B, RL952) were treated with the TORC1/2 inhibitor TAK228 or vehicle for one hour and protein concentrations were analyzed by reverse phase protein arrays (RPPA). We examined baseline protein and changes in individual proteins after treatment with TAK228 to determine correlations with sensitivity to TAK228. Identified proteins were then targeted with single agent pharmacologic inhibition and cytotoxicity measured by XTT analysis. Target inhibition was validated using WB analysis. Cooperativity in cytotoxicity for relevant combinations was measured using the methods of Chou-Talalay. Other phenotypic endpoints including migration, cell cycle alterations by flow cytometry and cell growth using live cell imaging were also collected. Results: Based on proteomics analysis, altered phosphorylation of CHK1(S296), CHK2(T68) and increasing concentration of VEGFR2 were strongly correlated with TAK228 resistance. TAK228 (TORC1/2, IC50 4-20nM), AZD7762 (CHK1/2, IC50 15-160nM), LY2603618 (CHK1, IC50 260nM-7.5mM) and cediranib (VEGFR2, 800nM-1mM) all had significant cytotoxic effects as individual agents on multiple endometrial cell lines. AZD7762 in combination with TAK228 led to synergism in all cell lines tested (mean combination index, 0.2-0.8). Single agent AZD7762 increased the number of cells in S-Phase and decreased cellular migration. Addition of recombinant VEGF-A to cell culture enhanced resistance to TAK228 in a dose dependent manner as measured by cell growth assays using live cell imaging. Combination of cediranib and TAK228 also showed significant synergism in multiple cell lines. Conclusions: RPPA identified changes in phosphorylated CHK1/2 and total VEGFR2 as being correlated to resistance to dual TORC1/2 inhibition with TAK228 in multiple endometrial cancer cell lines. While single agent activity of TORC1/2, CHK1/2 and VEGFR2 inhibitors showed varying activity, combinations of TAK228 with either cediranib or AZD7762 showed significant synergism in multiple cell lines. Clinical examination of these combinations agents may prove useful in recurrent endometrial cancer.
Collapse
Affiliation(s)
- Katie McGreal
- The Ohio State University James Comprehensive Cancer Center, Columbus, OH
| | | | - Jason David
- The Ohio State University Comprehensive Cancer Center, Columbus, OH
| | - Colin W. Stets
- The Ohio State Comprehensive Cancer Center, Columbus, OH
| | | | - James Lin Chen
- The Ohio State University Comprehensive Cancer Center, Columbus, OH
| | - John L. Hays
- The Ohio State University Comprehensive Cancer Center, Columbus, OH
| |
Collapse
|
3
|
Horne Z, Manire M, Crafton S, Miller E, Nakayama J, Morse C, Krivak T, Glaser S, Teterichko S, Beriwal S. OC-0299 Is pelvic radiation the right approach after surgery for FIGO IB grade 3 or type II uterine cancers? Radiother Oncol 2021. [DOI: 10.1016/s0167-8140(21)06846-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
4
|
Billingsley CC, Jacobson S, Crafton S, Crim A, Li Q, Hade E, Cohn DE, Fowler J, Copeland LJ, Salani R, Backes FJ, O'Malley DM. Evaluation of the hematologic safety of same day versus standard administration of pegfilgrastim in gynecology oncology patients undergoing platinum-based chemotherapy. J Clin Oncol 2014. [DOI: 10.1200/jco.2014.32.15_suppl.5569] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | | | - Sarah Crafton
- Ohio State University Wexner Medical Center, Columbus, OH
| | - Aleia Crim
- Ohio State University Wexner Medical Center, Columbus, OH
| | - Quan Li
- Ohio State University Wexner Medical Center, Columbus, OH
| | - Erinn Hade
- The Ohio State University Center for Biostatistics, Columbus, OH
| | - David E. Cohn
- Division of Gynecologic Oncology, The Ohio State University, Columbus, OH
| | - Jeffrey Fowler
- The Ohio State University Comprehensive Cancer Center, Hilliard, OH
| | | | | | | | - David M. O'Malley
- Ohio State University Wexner Medical Center, Dept of OB/GYN, Columbus, OH
| |
Collapse
|
5
|
Crafton S, Abdel-Rasoul M, Isley M. Pregnancy termination practice patterns among maternal fetal medicine specialists. Contraception 2013. [DOI: 10.1016/j.contraception.2013.05.049] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|